Sanofi’s Olivier Brandicourt has said acquisitions will help the French drugmaker grow, but the CEO has been unable to pull off a major deal.

In this week's FiercePharmaAsia wrap-up, Astellas terminated an unfruitful vaccine deal, Takeda made a rare disease R&D pact, China's Sanpower…

Privately held Kaléo will roll out its competing autoinjector next month at a price of $0 for most patients.

Mallinckrodt agreed to pay $100 million and license one of its products to a competitor to wrap up an FTC probe.

The same way they do to vote for a favorite singer on “The Voice,” consumers can now text Pfizer for a discount on erectile dysfunction drug Viagra.

Allergan officially has its first FDA approval of the year in hand with rosacea treatment Rhofade. But it may have to snag share from laser treatments.

A new report commissioned by industry group PhRMA lends credibility to the argument that a complex distribution system plays a role in high drug costs.

The leadership changes just keep on coming at GlaxoSmithKline. The latest? Global pharma president Abbas Hussain is out, and AstraZeneca vet Luke Miels is in.…

Here’s a radical solution for hepatitis C treatment in the U.S.: The government could buy Gilead Sciences. Price: $156 billion. Payoff: Curing hep C patients…